Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Oxaliplatin, 5-FU, and Radiation in Locally Advanced Rectal Cancer
NCT00006094Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2000
- Primary completion
- Oct 2006
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in rectal cancer, sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose of Oxaliplatin at 7 days, Progression-Free Survival up to 5 years and 2 more. Started Jul 2000; status: completed.
02
Drugs
oxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00006094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006094.